In addition to prevalent AR mutations, tumour samples from patients with mCRPC are enriched for mutations in TP53, DNA damage repair genes, RB1 and PTEN, contributing to their loss-of-function and overall genomic instability [31,32]. The gene discussed is TP53; the disease is neoplasm.